Ethos Col: MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos Therapy: Feasibility Study

Sponsor
Recherche clinique (Other)
Overall Status
Recruiting
CT.gov ID
NCT05909111
Collaborator
Varian Medical Systems (Industry)
15
1
1
38
0.4

Study Details

Study Description

Brief Summary

Current management of patients treated with External Beam Radiation Therapy (EBRT) for cervical cancer with a classical Image-guided Radiation Therapy (IGRT) strategy involves a complex, not entirely satisfactory, treatment workflow. Indeed, in our institution, two workflows have been designed to take into account the inter-fraction motion of cervix and uterus : an Internal Target Volume (ITV)-based approach and a plan of the day strategy requiring both several planning-CT (Computed Tomography) acquisitions with variable bladder filling.The upcoming installation of a Varian Ethos therapy system in our institution will allow us to implement a less cumbersome online adaptive radiotherapy strategy (oART), which, by conforming to the daily anatomy, will enable a reduction in the Clinical Target Volume (CTV) to Planning Target Volume (PTV) margins leading to an expected reduction in dose delivered to organs at risk (OAR) .On the other hand, MR (Magnetic Resonance)-only treatment planning is playing an increasing role in radiotherapy, notably in the treatment of prostate cancer. MR-only workflows are known (a) to provide the most reliable delineation in soft tissues and (b) to decrease spatial uncertainties by suppressing the Magnetic Resonance Imaging (MRI)-CT co-registration. Regarding the management of cervical cancer, the importance of MRI is well established and its use becomes essential. Combining a MR-only workflow with an adaptative one on the Varian Ethos system, could lead to an improved management of patients treated for cervical cancer with an expected reduction in margins and volumes treated (thanks to MRI delineation and online adaptation) and therefore a reduction of OAR toxicity. Including regular multi-parametric MR imaging during and after the course of the treatment could also provide in the future an assessment of the treatment response. One of the important challenges in developing this specific workflow is to have a reliable synthetic CT (derived from MRI) to (a) provide electron or mass density for treatment planning calculations and (b) allow accurate online repositioning/deformation with Ethos Cone Beam Computed Tomography (CBCT). The other fundamental challenge is to provide a formal assessment of the clinical benefit of introducing MR-only simulation and planning in an oART workflow.

This project aims to demonstrate the feasibility of setting up an adaptive workflow on the ETHOS platform with the sole use of MR patient image.The project is divided into two parts. The first part consists in demonstrate the feasibility of the workflow on 15 patients with cervix cancer.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Magnetic resonance imaging
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
15 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
MR-Only Based Adaptive External Beam Radiation Therapy of Cervical Cancer on Ethos
Actual Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: MRI assessment during radiation therapy course

Patients perform on MRI every week during the 5-weeks treatment

Diagnostic Test: Magnetic resonance imaging
MRI weekly during the radiation treatment course (5 RMI added to the standard care)

Outcome Measures

Primary Outcome Measures

  1. Tumor regression assessment CBCT [18 months]

    Volume Tumor regression on CBCT

  2. Tumor regression assessment MRI [18 months]

    Volume Tumor regression on MRI

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 years old

  • Histologically proven cervical cancer (SCC, ADK ou adenous-SCC)

  • Patient for curative RTCT treatment

  • FIGO/TNM Stage IB2, IIA, IIB, IIIA, IIIB with or without lymph nodes involvement

  • WHO < 2

  • No pregnancy

  • Informed consent dated and signed

  • Patient affiliated or beneficiary of a social security scheme

  • Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

Exclusion Criteria:
  • Metastatic disease

  • Contraindications to IRM examinations (claustrophobia, presence of metallic elements..)

  • Signes of active infection or serious health problems

  • Historic of abdominal or pelvis RT

  • Surgical history: partial or total hysterectomy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut Sainte Catherine Avignon France

Sponsors and Collaborators

  • Recherche clinique
  • Varian Medical Systems

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Recherche clinique, Principal Investigator, Institut Sainte Catherine
ClinicalTrials.gov Identifier:
NCT05909111
Other Study ID Numbers:
  • COL-ETHOS
First Posted:
Jun 18, 2023
Last Update Posted:
Jun 18, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2023